<SEC-DOCUMENT>0001193125-22-247417.txt : 20220920
<SEC-HEADER>0001193125-22-247417.hdr.sgml : 20220920
<ACCEPTANCE-DATETIME>20220920073454
ACCESSION NUMBER:		0001193125-22-247417
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220920
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220920
DATE AS OF CHANGE:		20220920

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Wave Life Sciences Ltd.
		CENTRAL INDEX KEY:			0001631574
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			U0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37627
		FILM NUMBER:		221252078

	BUSINESS ADDRESS:	
		STREET 1:		7 STRAITS VIEW
		STREET 2:		#12-00, MARINA ONE EAST TOWER
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			018936
		BUSINESS PHONE:		617-949-2900

	MAIL ADDRESS:	
		STREET 1:		733 CONCORD AVENUE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WAVE Life Sciences Ltd.
		DATE OF NAME CHANGE:	20170516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences Ltd.
		DATE OF NAME CHANGE:	20151106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences LTD.
		DATE OF NAME CHANGE:	20151106
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d369218d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:wve="http://www.wavelifesciences.com/20220920" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-09-20_to_2022-09-20">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-09-20_to_2022-09-20">0001631574</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="wve-20220920.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-09-20_to_2022-09-20"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-20</xbrli:startDate> <xbrli:endDate>2022-09-20</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-09-20_to_2022-09-20">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-09-20_to_2022-09-20" format="ixt:datemonthdayyearen">September&#160;20, 2022</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-09-20_to_2022-09-20">WAVE LIFE SCIENCES LTD.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-09-20_to_2022-09-20" format="ixt-sec:edgarprovcountryen">Singapore</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-09-20_to_2022-09-20">001-37627</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-09-20_to_2022-09-20">00-0000000</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-09-20_to_2022-09-20">7 Straits View #12-00</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2022-09-20_to_2022-09-20">Marina One</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-09-20_to_2022-09-20">East Tower</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCountry" contextRef="duration_2022-09-20_to_2022-09-20" format="ixt-sec:countrynameen">Singapore</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-09-20_to_2022-09-20">018936</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: +<ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-09-20_to_2022-09-20">65</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-09-20_to_2022-09-20">6236 3388</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="text-decoration:underline">see</span> General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-09-20_to_2022-09-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-09-20_to_2022-09-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-09-20_to_2022-09-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-09-20_to_2022-09-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-09-20_to_2022-09-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-09-20_to_2022-09-20">$0 Par Value Ordinary Shares</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-09-20_to_2022-09-20">WVE</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-09-20_to_2022-09-20" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;20, 2022, Wave Life Sciences Ltd. (the &#8220;Company&#8221; or &#8220;Wave&#8221;) issued a press release announcing a positive update to its ongoing Phase 1b/2a <span style="white-space:nowrap">SELECT-HD</span> trial of <span style="white-space:nowrap">WVE-003,</span> the Company&#8217;s clinical candidate for Huntington&#8217;s disease (HD). <span style="white-space:nowrap">SELECT-HD</span> is an adaptive trial designed to rapidly optimize dose level and frequency based on early indicators of target engagement. The trial update was driven by the observation of reductions of mutant huntingtin (mHTT) protein in cerebrospinal fluid (CSF) after study participants received either a single 30 or 60 mg dose of <span style="white-space:nowrap">WVE-003.</span> In addition, wild-type huntingtin (wtHTT) protein was preserved, which appears consistent with allele-selectivity. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The press release also indicated that Wave management will host an investor conference call at 8:30 a.m. ET on September&#160;20, 2022 to discuss these initial results and provide a business update. For purposes of the call, and in connection with the announcement described above, the Company plans to share an investor slide presentation during the investor conference call, which will be available on the &#8220;For Investors&#160;&amp; Media&#8221; section of the Company&#8217;s website at<span style="text-decoration:underline">&#160;http://ir.wavelifesciences.com/</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The information in this Item 7.01 is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </span></p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth in the press release referred to in Item 7.01 above, other than the second, third and ninth paragraphs thereof, is incorporated by reference into this Item 8.01 of this Current Report <span style="white-space:nowrap">on&#160;Form&#160;8-K.</span> </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d369218dex991.htm">Press Release issued by Wave Life Sciences Ltd. on September&#160;20, 2022 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:92%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">WAVE LIFE SCIENCES LTD.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">/s/ Paul B. Bolno, M.D.</span></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Paul B. Bolno, M.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: September&#160;20, 2022 </p>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d369218dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g369218g0920082350437.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Wave Life Sciences Announces Positive Update from Phase 1b/2a
<FONT STYLE="white-space:nowrap">SELECT-HD</FONT> Trial with Initial Results Indicating Allele-Selective Target Engagement with <FONT STYLE="white-space:nowrap">WVE-003</FONT> in Huntington&#146;s Disease </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Single doses of <FONT STYLE="white-space:nowrap">WVE-003</FONT> appear generally safe and well-tolerated </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 or 60 mg; mean mHTT reduction across both cohorts was 22%
(median reduction 30%) from baseline 85 days post-single dose </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Wild-type huntingtin (wtHTT) protein levels through day 85 appear
consistent with allele-selectivity </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Expanding single dose cohorts to optimize dose level with data expected in 1H 2023 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Continued clinical validation of PRISM platform and PN stereochemistry </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Wave to host investor conference call and webcast at 8:30 a.m. ET today </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CAMBRIDGE, Mass., September</B><B></B><B>&nbsp;20, 2022 </B>&#150; Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company
committed to delivering life-changing treatments for people battling devastating diseases, today announced a positive update to the ongoing Phase 1b/2a <FONT STYLE="white-space:nowrap">SELECT-HD</FONT> clinical trial of <FONT
STYLE="white-space:nowrap">WVE-003,</FONT> the company&#146;s clinical candidate for Huntington&#146;s disease (HD). <FONT STYLE="white-space:nowrap">SELECT-HD</FONT> (NCT05032196) is an adaptive trial designed to rapidly optimize dose level and
frequency based on early indicators of target engagement. The trial update announced today is being driven by the observation of reductions in mutant huntingtin (mHTT) protein in cerebrospinal fluid (CSF) after study participants received either a
single 30 or 60 mg dose of <FONT STYLE="white-space:nowrap">WVE-003.</FONT> Additionally, wild-type huntingtin (wtHTT) protein was preserved, which appears consistent with allele-selectivity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;These preliminary data suggest <FONT STYLE="white-space:nowrap">WVE-003</FONT> is working as intended: to selectively reduce the toxic mHTT protein
while avoiding targeting the healthy, wild-type huntingtin protein, thereby preserving its beneficial effects in the central nervous system,&#148; said Ralf Reilmann, MD, founder of the George-Huntington Institute, Muenster, Germany and member of
the <FONT STYLE="white-space:nowrap">SELECT-HD</FONT> Clinical Advisory and Dose Escalation Committees. &#147;Additionally, I am encouraged by the safety and tolerability data. Taken together, <FONT STYLE="white-space:nowrap">WVE-003</FONT> appears
to have a unique profile with the potential to overcome prior therapeutic challenges in this field. Furthermore, as a clinician and researcher focused on HD, it is my hope that innovative adaptive trial designs like
<FONT STYLE="white-space:nowrap">SELECT-HD</FONT> become more commonplace to optimize dosing in early <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies. It is also exciting to finally see an
assay measuring wtHTT being developed and used successfully in a clinical trial &#150; a long awaited, big step forward for the HD research community. The availability of this assay has potential to significantly increase our understanding of how
best to treat this challenging disease.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Based on these initial data, it appears that our preclinical data for
<FONT STYLE="white-space:nowrap">WVE-003</FONT> are translating in the clinic,&#148; said Michael Panzara, MD, MPH, Chief Medical Officer and Head of Therapeutics Discovery and Development at Wave Life Sciences. &#147;We are encouraged to see a mean
CSF mHTT reduction from baseline of 22% at day 85 after participants received just a single dose of <FONT STYLE="white-space:nowrap">WVE-003,</FONT> demonstrating a compelling pharmacological profile for individuals with HD. We are grateful to the
HD community, including the <FONT STYLE="white-space:nowrap">SELECT-HD</FONT> participants, study sites and advisors, for their continued partnership and support of this program. We look forward to continuing to expand this study and sharing
additional data next year.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eighteen (18)&nbsp;participants have been dosed in the <FONT STYLE="white-space:nowrap">SELECT-HD</FONT>
trial (30 mg, n=4; 60 mg, n=4; 90 mg, n=4; placebo, n=6). Participants enrolled at 30 mg, 60 mg and placebo had adequate <FONT STYLE="white-space:nowrap">follow-up</FONT> to day 85 for biomarker analysis. At the time of analysis, none of the
participants dosed with 90 mg had reached day 85 so this cohort is not included in the biomarker analysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key observations include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Single doses of <FONT STYLE="white-space:nowrap">WVE-003</FONT> up to 90 mg appeared generally safe and
well-tolerated </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adverse events (AEs) were balanced across treatment groups, including placebo, and all were mild to moderate in
intensity </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No serious adverse events (SAEs) were observed </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No participants discontinued from the study </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Among participants in the 30 and 60 mg <FONT STYLE="white-space:nowrap">WVE-003</FONT> cohorts, the mean
reduction in CSF mHTT from baseline was 22% (median reduction 30%) at 85 days following a single dose </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The difference in the mean reduction in CSF mHTT compared to placebo was 35% at 85 days post-single dose
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For these analyses, the 30 and 60 mg single dose cohorts were pooled as there was no apparent dose response
between these two cohorts. Wave will continue to evaluate dose response in the expanded single dose cohorts </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In the 30 and 60 mg cohorts, wtHTT protein was preserved, which appears consistent with allele-selectivity
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Increases in neurofilament light chain (NfL) from baseline were observed in some participants. Wave will continue
to monitor trends in NfL as <FONT STYLE="white-space:nowrap">SELECT-HD</FONT> advances </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There were no clinically meaningful elevations in CSF white blood cell counts or protein that would indicate
inflammation in the CNS </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There were no meaningful changes in clinical outcome measures, although the dataset and duration were not
sufficient to assess clinical effects </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on these data, Wave is adapting the <FONT STYLE="white-space:nowrap">SELECT-HD</FONT>
clinical trial to expand the single dose cohorts and will also continue advancing the 90 mg cohort for biomarker analysis at day 85. Additional single dose biomarker and safety data are expected in the first half of 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave&#146;s approach to HD is guided by the recognition that, in addition to a gain of function of the mHTT protein, people with this disease have lost one
copy of the wtHTT allele, leaving them with a smaller protective reservoir of healthy protein than unaffected individuals. wtHTT protein is critical for neuronal function and suppression may have detrimental long-term consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">WVE-003</FONT> is the only allele-selective HD candidate in clinical development. It is designed to preferentially lower mHTT
by targeting a single nucleotide polymorphism (SNP3) that appears on the mHTT allele and is not present on the wtHTT allele. Based upon scientific literature, it is estimated that approximately 40&nbsp;percent of adults with HD carry SNP3 in
association with the HD mutation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;These <FONT STYLE="white-space:nowrap">SELECT-HD</FONT> data are the first to support the feasibility of
allele-selective mHTT knockdown in the clinic &#150; a precision approach enabled by our PRISM discovery and drug development platform,&#148; said Paul Bolno, MD, MBA, President and Chief Executive Officer at Wave Life Sciences. <FONT
STYLE="white-space:nowrap">&#147;SELECT-HD</FONT> is the second clinical trial this year to demonstrate clinical translation of Wave&#146;s PN backbone chemistry modifications, as well as the impact of rational design through control of
stereochemistry, increasing our conviction in our platform. We look forward to sharing data from our splicing clinical program in muscle &#150; <FONT STYLE="white-space:nowrap">WVE-N531</FONT> for exon 53 skipping in Duchenne muscular dystrophy
&#150; in the fourth quarter of 2022.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Conference Call and Webcast </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave management will host an investor conference call today at 8:30 a.m. ET to discuss the <FONT STYLE="white-space:nowrap">SELECT-HD</FONT> clinical trial
update. The webcast of the conference call may be accessed by visiting &#147;Events&#148; on the investor relations section of the Wave Life Sciences corporate website:
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ir.wavelifesciences.com/events-and-presentations.</FONT></FONT> Analysts planning to participate during the Q&amp;A portion of the live call can join the conference call at the audio
conferencing link available here. It is recommended that participants register at least 15 minutes in advance of the call. Once registered, participants will receive the <FONT STYLE="white-space:nowrap">dial-in</FONT> information. Following the live
event, an archived version of the webcast will be available on the Wave Life Sciences website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the
<FONT STYLE="white-space:nowrap">SELECT-HD</FONT> Clinical Trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">SELECT-HD</FONT> trial is a global, multicenter,
randomized, double-blind, placebo-controlled Phase 1b/2a clinical trial to assess the safety and tolerability of single- and multiple-ascending intrathecal doses of <FONT STYLE="white-space:nowrap">WVE-003</FONT> in people with a confirmed diagnosis
of HD who are in the early stages of the disease and carry SNP3 in association with their cytosine-adenine-guanine (CAG) expansion. Additional objectives include assessing the plasma pharmacokinetic profile and exposure in the cerebrospinal fluid,
as well as exploratory pharmacodynamic (mHTT, wtHTT and neurofilament light chain) and clinical endpoints. The <FONT STYLE="white-space:nowrap">SELECT-HD</FONT> trial is expected to enroll approximately 36 participants. It is designed to be
adaptive, with dose escalation and dosing frequency being guided by an independent committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Huntington&#146;s Disease </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Huntington&#146;s disease (HD) is a debilitating and ultimately fatal autosomal dominant neurological disorder, characterized by cognitive decline, psychiatric
illness, and chorea. HD causes nerve cells in the brain to deteriorate over time, affecting thinking ability, emotions, and movement. HD is caused by an expanded cytosine-adenine-guanine (CAG) triplet repeat in the huntingtin (HTT) gene that results
in production of mutant HTT (mHTT) protein. Accumulation of mHTT causes progressive loss of neurons in the brain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately 30,000 people in the
United States have symptomatic HD and more than 200,000 others are at risk for developing the disease. There are currently no approved disease-modifying therapies available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About PRISM<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PRISM is Wave Life Sciences&#146; proprietary discovery and drug development platform that enables genetically defined diseases to be targeted with stereopure
oligonucleotides across multiple therapeutic modalities, including silencing, splicing, and editing. PRISM combines the company&#146;s unique ability to construct stereopure oligonucleotides with a deep understanding of how the interplay among
oligonucleotide sequence, chemistry and backbone stereochemistry impacts key pharmacological properties. By exploring these interactions through iterative analysis of <I>in vitro</I> and <I>in vivo</I> outcomes and machine learning-driven predictive
modeling, the company continues to define design principles that are deployed across programs to rapidly develop and manufacture clinical candidates that meet <FONT STYLE="white-space:nowrap">pre-defined</FONT> product profiles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Wave Life Sciences </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave Life Sciences (Nasdaq:
WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> medicines across multiple therapeutic modalities using PRISM, the company&#146;s proprietary discovery and drug development platform that enables the
precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.
To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements concerning our goals, beliefs, expectations, strategies, objectives and plans and other statements that
are not necessarily based on historical facts, which are within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding: our belief as to what our initial <FONT
STYLE="white-space:nowrap">WVE-003</FONT> data indicating allele-selective target engagement announced above portend for our ability to deliver meaningful therapies for people living with HD and their families; the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> nature of our initial <FONT STYLE="white-space:nowrap">WVE-003</FONT> data to support the feasibility of allele-selective mHTT knockdown in the clinic; the continued dosing and
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generation of data to complete our <FONT STYLE="white-space:nowrap">SELECT-HD</FONT> adaptive study and the announcement of such events; our expectations regarding the timing of additional data
in the <FONT STYLE="white-space:nowrap">SELECT-HD</FONT> study; the potential of our <I>in vitro</I> and <I>in vivo</I> preclinical data and modelling to predict the relevant dosing and behavior of our compounds in humans; the potential benefits of
PRISM, including our novel PN backbone chemistry modifications<B> </B>and the impact of rational design through control of stereochemistry; and our expectations regarding the timing of sharing data from our third clinical candidate containing PN
chemistry, <FONT STYLE="white-space:nowrap">WVE-N531</FONT><B> </B>for exon 53 skipping in Duchenne muscular dystrophy. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important
factors, including the following: our ability to finance our drug discovery and development efforts and to raise additional capital when needed; the ability of our preclinical programs to produce data sufficient to support our clinical trial
applications and the timing thereof; the clinical results of our programs and the timing thereof, which may not support further development of product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress
of clinical trials, including their receptiveness to our adaptive trial designs; our effectiveness in managing future clinical trials and regulatory interactions; the effectiveness of PRISM, including our novel PN backbone chemistry modifications;
the effectiveness of our novel ADAR-mediated RNA editing platform capability and our AIMers; the continued development and acceptance of oligonucleotides as a class of medicines; our ability to demonstrate the therapeutic benefits of our candidates
in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our dependence on third parties, including contract research organizations, contract manufacturing organizations, collaborators and partners; our
ability to manufacture or contract with third parties to manufacture drug material to support our programs and growth; our ability to obtain, maintain and protect our intellectual property; our ability to enforce our patents against infringers and
defend our patent portfolio against challenges from third parties; competition from others developing therapies for similar indications; our ability to maintain the company infrastructure and personnel needed to achieve our goals; the severity and
duration of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and variants thereof, and its negative impact on the conduct of, and the timing of enrollment, completion and reporting with respect to our clinical trials; and any other
impacts on our business as a result of or related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, as well as the information under the caption &#147;Risk Factors&#148; contained in our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> filed with the Securities and Exchange Commission (SEC) and in other filings we make with the SEC from time to time. We undertake no obligation to update the information contained in this press release to
reflect subsequently occurring events or circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Rausch </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-949-4827</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">krausch@wavelifesci.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alicia Suter </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">617-949-4817</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">asuter@wavelifesci.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HD Community Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chelley Casey </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">774-276-8738</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ccasey@wavelifesci.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>wve-20220920.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 9/20/2022 2:46:42 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:wve="http://www.wavelifesciences.com/20220920"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.wavelifesciences.com/20220920"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wve-20220920_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wve-20220920_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>wve-20220920_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 9/20/2022 2:46:42 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>wve-20220920_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 9/20/2022 2:46:42 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="wve-20220920.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g369218g0920082350437.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g369218g0920082350437.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !^ *$# 2(  A$! Q$!_\0
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MBF( (_W3UQ7'./\ <:.^G+3^(I?=?^OD3S:%9SV]S"?,"W$OG,=^XJ_'(W9
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MKSN>5^:^I])[&GR*%M%^FPFT>@_*BEHJ30***8)HB^P2)O\ [NX9H ?1110
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MTIA;/D\F/K&?R^7_ (#7H6JZ;;ZQI-WIMVFZWNH6AD'LPQ^= '+_  L\4_\
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M.>,?UHTJQFM;F^2>43(=BQL<[B@7 W>_;/?&:K&_FT%(;"6-9T VV[A]IV]
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+OW?<7J***R.L_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139734448295392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 20, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001631574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 20,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">WAVE LIFE SCIENCES LTD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">U0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7 Straits View #12-00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Marina One<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">East Tower<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">SG<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">018936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">6236 3388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">$0 Par Value Ordinary Shares<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">WVE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d369218d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="wve-20220920.xsd" xlink:type="simple"/>
    <context id="duration_2022-09-20_to_2022-09-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <startDate>2022-09-20</startDate>
            <endDate>2022-09-20</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2022-09-20_to_2022-09-20">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-09-20_to_2022-09-20"
      id="Hidden_dei_EntityCentralIndexKey">0001631574</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-09-20_to_2022-09-20">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-09-20_to_2022-09-20">2022-09-20</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-09-20_to_2022-09-20">WAVE LIFE SCIENCES LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-09-20_to_2022-09-20">U0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-09-20_to_2022-09-20">001-37627</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-09-20_to_2022-09-20">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-09-20_to_2022-09-20">7 Straits View #12-00</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2022-09-20_to_2022-09-20">Marina One</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-09-20_to_2022-09-20">East Tower</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="duration_2022-09-20_to_2022-09-20">SG</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-09-20_to_2022-09-20">018936</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-09-20_to_2022-09-20">65</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-09-20_to_2022-09-20">6236 3388</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-09-20_to_2022-09-20">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-09-20_to_2022-09-20">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-09-20_to_2022-09-20">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-09-20_to_2022-09-20">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-09-20_to_2022-09-20">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="duration_2022-09-20_to_2022-09-20">$0 Par Value Ordinary Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-09-20_to_2022-09-20">WVE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-09-20_to_2022-09-20">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %L\-%4D'INBK0   /@!   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( %L\-%5ED'F2&0$  ,\#   3              "  :T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d369218d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d369218d8k.htm">d369218d8k.htm</File>
    <File>d369218dex991.htm</File>
    <File>wve-20220920.xsd</File>
    <File>wve-20220920_lab.xml</File>
    <File>wve-20220920_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d369218d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d369218d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "wve-20220920_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "wve-20220920_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "wve-20220920.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "wve",
   "nsuri": "http://www.wavelifesciences.com/20220920",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d369218d8k.htm",
      "contextRef": "duration_2022-09-20_to_2022-09-20",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d369218d8k.htm",
      "contextRef": "duration_2022-09-20_to_2022-09-20",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.wavelifesciences.com//20220920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-22-247417-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-247417-xbrl.zip
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MJ=5D:V260(YH7@;/#LKSRGR/E]DWO#,BD[30V&:PO2(S;U2R0 <P_^9;OOD
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M57S#6?=]_9G\C2W+YBM(+N" 2D$'3&F*T>H"FYC.50/M<, E$TVZLRX=+22
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MQ*/;Q&-)+!;']_G@G_B0_R.)_PU02P,$%     @ 6SPT576UV=)' P  : L
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MD;Z+47^R17R\O[=?.-0I=(2Q15/\4*0+UH=4D?!69:!<![)"D%9R!KWM)LK
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M"P  $               @ %N+0  =W9E+3(P,C(P.3(P+GAS9%!+ 0(4 Q0
M   ( %L\-%485#59: 8  '9&   4              "  >,P  !W=F4M,C R
M,C Y,C!?;&%B+GAM;%!+ 0(4 Q0    ( %L\-%5_2P&JO 0  #<L   4
M          "  7TW  !W=F4M,C R,C Y,C!?<')E+GAM;%!+!08     !0 %
+ #T!  !K/      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
